Keywords: acambis, narrows, first-half, loss, uk, vaccines, developer
Acambis narrows first-half 2008 loss 37%
Article | 18 August 2008
UK vaccines developer Acambis' interim pretax loss in the first six months of 2008 narrowed 36.8% to L12.2 million ($23.9 million), as revenues ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
